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Oxytocin’s inhibitory effect on food intake is stronger in obese
than normal-weight men
M Thienel1, A Fritsche2,3,4, M Heinrichs5,6, A Peter2,3,4, M Ewers1, H Lehnert7, J Born1,2,3 and M Hallschmid1,2,3
BACKGROUND/OBJECTIVES: Animal studies and pilot experiments in men indicate that the hypothalamic neuropeptide oxytocin
limits food intake, and raise the question of its potential to improve metabolic control in obesity.
SUBJECTS/METHODS: We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on
ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men. In
double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min
after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake. Energy expenditure was
repeatedly assessed by indirect calorimetry and blood was sampled to determine concentrations of blood glucose and hormones.
RESULTS: Oxytocin markedly reduced hunger-driven food intake in the fasted state in obese but not in normal-weight men, and
led to a reduction in snack consumption in both groups, whereas energy expenditure remained generally unaffected.
Hypothalamic–pituitary–adrenal axis secretion and the postprandial rise in plasma glucose were blunted by oxytocin in both
groups.
CONCLUSIONS: Oxytocin exerts an acutely inhibitory impact on food intake that is enhanced rather than decreased in obese
compared with normal-weight men. This pattern puts it in contrast to other metabolically active neuropeptides and bodes well for
clinical applications of oxytocin in the treatment of metabolic disorders.
International Journal of Obesity (2016) 40, 1707–1714; doi:10.1038/ijo.2016.149
INTRODUCTION
Oxytocin, a hypothalamic nonapeptide which is released into the
circulation through the posterior pituitary and also directly acts on
central nervous receptors, regulates reproductive functions like
mother–infant interaction and lactation and is a potent modulator
of social behaviours including attachment and sexual behaviour.1
Studies in animals and pilot experiments in humans have
indicated that oxytocin moreover might have a role in the
regulation of eating behaviour and metabolism. In rodents2 and
rhesus monkeys3 with normal weight, but also with diet-induced
obesity, subcutaneous oxytocin administration inhibits food
intake, increases energy expenditure and reduces glucose levels.
Interestingly, experiments in rodents suggest that the metabolic
effects of oxytocin may be even enhanced in diet-induced obese
in comparison to control animals.4 In studies in humans, intranasal
oxytocin attenuated reward-driven snack intake and decreased
postprandial glucose concentrations in normal-weight men.5
Against this background, and considering that available weight
loss treatments are of modest or temporary efﬁcacy,6,7 the
intranasal administration of oxytocin to the human brain, which
in a broad range of studies has been demonstrated to be
associated with absent or minimal side effects,8 might be a
promising pharmacological intervention in obesity.9–11
In the present study, we investigated the impact of oxytocin on
eating behaviour in obese men and compared the results with the
effects obtained in normal-weight men.5 As ingestive behavior is
homeostatically regulated in response to energy depletion
as well as by brain circuits processing the reward-related, ‘hedonic’
qualities of food intake,12,13 we applied a validated paradigm that
includes a breakfast buffet presented to fasted participants,14,15 as
well as the delayed assessment of food intake from snacks.16,17 In
addition, energy expenditure, glucose homeostasis and hypotha-
lamic–pituitary–adrenal (HPA) axis secretory activity were mea-
sured before and after oxytocin administration as well as after
breakfast intake.
MATERIALS AND METHODS
Subjects
Eighteen healthy obese men were recruited and their results compared
with the ﬁndings in 20 normal-weight men, which were obtained with an
identical experimental set-up and are described in detail in Ott et al
(reprinted with permission from ref. 5; copyright 2013 American Diabetes
Association). Subjects were recruited via mailing lists and advertisements
in local newspapers. Relevant illness was excluded by medical history and
clinical examination. Habitual eating behaviour of obese subjects was
assessed via a lifestyle questionnaire on dietary restraint and tendency
toward disinhibition. Dietary restraint, that is, the conscious effort to
restrict calorie intake to control body weight, was assessed using the
restraint scale of the Dutch Eating Behaviour Questionnaire (DEBQ-R).18
Tendency toward disinhibition was assessed with the disinhibition scale of
the Three Factor Eating Questionnaire (TFEQ).19 On average, participants
achieved a DEBQ-R score (± s.e.m.) of 2.55±0.13 and a TFEQ score of
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6.53± 0.80. The propensity to consume palatable foods was measured at
three levels of food proximity (food available, food present and food
tasted) with the Power of Food Scale (PFS)20 at each session (see Table 1
for subject characteristics). Subjects were kept unaware of hypothesized
treatment effects on food intake and were informed that the experiments
concerned the effect of oxytocin on mood, taste preferences and energy
expenditure. Participants gave written informed consent to the study that
conformed to the Declaration of Helsinki and was approved by the local
ethics committee.
Experimental procedure
Experiments were carried out in a balanced, double-blind, cross-over,
within-subject comparison. Each subject participated in two experimental
sessions (oxytocin and placebo) spaced at least 10 days apart. Participants
were instructed to abstain from the intake of food and caffeinated and
alcoholic beverages after 2000 hours on the day preceding each session.
After the subject’s arrival at the laboratory at ~ 0800 hours, a venous
cannula was inserted into the subject’s non-dominant arm to enable
drawing of venous blood (see Figure 1a for the experimental procedure).
Thereafter, blood was sampled for baseline assessments of hormonal
parameters. At 0942 hours each subject was intranasally administered
24 IU oxytocin (0.6 ml Syntocinon; Deﬁante Farmacêutica, Funchal/
Madeira, Portugal) or placebo (0.6 ml vehicle containing all Syntocinon
ingredients except for the peptide) at six individual 0.1 ml puffs (three per
alternating nostril) with 30-s intervals in-between. Forty-ﬁve minutes after
administration, subjects were presented with a free-choice ad libitum
breakfast buffet from 1030 to 1100 hours. Casual snack intake was
assessed 95 min later under the pretext of a snack taste test. Olfactory
function was tested at 1200 hours. Feelings of hunger, mood, subjective
well-being and the perceived experimenter’s trustworthiness were
repeatedly rated on visual analog scales (0–100) and energy expenditure
was assessed by indirect calorimetry before and after substance
administration and after the test breakfast. Heart rate and blood pressure
were monitored. At the end of the experiments, subjects were asked to
indicate their account of the study purpose and if they thought to have
received oxytocin or placebo.
Assessments of food intake
The breakfast buffet comprised a collection of bread and rolls, spreads (for
example, jam, honey), sausages, cheese, fruits, puddings, fruits, milk and
juice, which totaled 4562 kcal (see Table 2 for details). Subjects were left
undisturbed during breakfast and were not aware that their food intake
was measured by weighing buffet components before and after. This
procedure enables the precise assessment of primarily hunger-driven food
intake in the fasted state.5,14,15 Reward-related eating in the relative
absence of hunger was assessed under the pretext of a taste test5,16,17 that
included snacks of three different types but comparable calorie content
and macronutrient composition, that is, ‘TUC Cracker Classic’ (salty taste;
Griesson-de Beukelaer, Polch, Germany; 500 kcal per 100 g; 57.2 g
carbohydrates per 100 g), ‘Rice Wafﬂes’ (bland taste; Continental Bakeries
B.V., Dordrecht, The Netherlands; 390 kcal per 100 g; 63 g carbohydrates
per 100 g), and ‘Double Chocolate Cookies’ (sweet taste; EDEKA, Hamburg,
Germany; 486 kcal per 100 g; 63 g carbohydrates per 100 g). For each
variety, 15 snacks broken into bite size pieces were provided on a separate
plate, and labeled snack A, B and C, respectively, allowing for a
considerable amount to be eaten without the plates appearing empty,
to ensure that participants would not restrict snack intake based on
whether the experimenter could see how much had been consumed. The
participant was instructed to taste and rate each snack type on a visual
analog scale anchored by 0 (not at all) and 100 mm (very palatable/sweet/
salty). Subjects were informed that during and after completion of the
rating they could eat as many snacks as they liked because remaining food
would be discarded, and were left alone for 10 min. Intake was covertly
measured by weighing the snacks before and after the test.
Measurement of hunger, thirst, mood, vigilance and olfactory
function
Hunger, thirst and the perceived trustworthiness of the experimenter were
rated on visual analog scale (0–100 mm). Self-reported mood was assessed
on 5-point scales covering the categories good/bad mood, alertness/
sleepiness and calmness/agitation (MDBF).21 In the 5-min personal
computer-based vigilance task,22 a red dot appears at random intervals
either on the left or the right side of the screen, and subjects are required
to press the respective key as fast as possible, receiving immediate
feedback in the form of the reaction time for correct responses or an error
message. Mean reaction time was registered and adjusted for mistakes by
adding the square root of the product of the mean reaction time and the
number of mistakes. Olfactory function was tested 60 min after the test
buffet with the validated Snifﬁn’ Sticks commercial test kit (Burghart
Elektro- und Feinmechanik GmbH, Wedel, Germany) that covers the three
dimensions of olfactory threshold, discrimination and identiﬁcation.23
Measurement of energy expenditure, plasma glucose and
hormonal parameters
Resting energy expenditure (expressed as kcal per day) and the respiratory
quotient were measured via indirect calorimetry using a DeltaTrac II
ventilated-hood system (SensorMedics Vmax 29n; VIASYS Healthcare,
Yorba Linda, CA, USA). Before each use, the device was calibrated with
calibration gas to 5% CO2 and 95% O2. Calorimetric measurements (30 min
each) took place at 0910 hours (baseline), immediately after intranasal
substance administration at 0945 hours to assess effects of intra-
nasal oxytocin alone, and again at 1110 hours (that is, after the ad
libitum test buffet) to register postprandial energy expenditure. Substrate
utilization in the obese participants was calculated based on the
following stoichiometric equations: carbohydrate oxidation (g per min) =
4.21× VCO2− 2.962× VO2− 0.4 × n; fat oxidation (g per min) = 1.695×
VO2− 1.701× VCO2− 1.77 × n where n represents nitrogen excretion from
protein oxidation (estimated at 135 μg× kg×min− 1).24
Blood samples obtained in the obese participants to assess serum
insulin, C-peptide, cortisol and growth hormone, as well as plasma glucose,
lactate, adrenocorticotropic hormone and non-esteriﬁed fatty acids (NEFA)
were centrifuged, and samples were stored at − 80 °C. Concentrations of
glucose and lactate in ﬂuoride plasma were determined with the ADVIA
Chemistry XPT clinical chemistry analyzer according to the hexokinase and
Table 1. Subject characteristics
Variable Obese men (mean± s.e.m.) Normal-weight men (mean± s.e.m.) P-value
Age (years) 27.83± 1.38 26.30± 0.89 0.35
Body weight (kg) 106.39± 2.25 74.81± 1.89 o0.001
BMI (kg m− 2) 32.10± 0.36 22.66± 0.36 o0.001
Lean body mass (kg) 79.96± 1.56 61.10± 1.40 o0.001
Body fat mass (kg) 26.54± 1.28 13.78± 0.84 o0.001
Body fat mass (% of total weight) 24.80± 0.92 18.19± 0.87 o0.001
Body cell mass (% of lean body mass) 56.37± 0.54 54.94± 0.60 0.09
Body water (liter) 58.53± 1.14 44.72± 1.02 o0.001
Phase angle (°) 7.00± 0.13 6.69± 0.13 0.10
PFS (total scale score) 2.71± 0.13 2.42± 0.14 0.13
Mean± s.e.m. values are indicated. Body composition was measured by bioelectrical impedance analysis (Nutriguard-M, Data Input, Germany) in a clinical
examination taking place shortly before the ﬁrst experimental session. PFS, total scale score of the Power of Food Scale (PFS), a measure of propensity to
consume palatable foods, assessed before substance administration and averaged across conditions. Obese men, n= 18; normal-weight men, n= 20.
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colorimetric lactatoxidase method, respectively. Serum insulin, C-peptide
and cortisol concentrations were measured with the ADVIA Centaur XPT
immunology analyzer and concentrations of growth hormone and
adrenocorticotropic hormone were measured using the Immulite 2000
XPi Immunoassay-System. Plasma NEFA were determined according to the
ACS-ACOD method (NEFA-HR(2), Wako Chemicals GmbH, Neuss, Germany)
with the ADVIA Chemistry XPT clinical chemistry analyzer (all instruments
from Siemens Healthcare Diagnostics, Eschborn, Germany).
Statistical analysis
Analyses were generally based on analyses of variance (ANOVA) with
the between-subject factor ‘group’ (obese/normal weight) and the
within-subject factors ‘treatment’ (oxytocin/placebo), ‘time’, ‘nutrient’
(carbohydrates/protein/fat), ‘food type’ (savoury/sweet/neutral), ‘snack
type’ (salty/sweet/bland) and ‘taste’ (salty/sweet) as appropriate. Note that
comparisons between groups focused on the main parameters of energy
intake and expenditure; for detailed results of normal-weight subjects see
Placebo Oxytocin
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Figure 1. Experimental procedure and food intake results. (a) After baseline assessments of blood parameters, psychological variables, vigilance and
energy expenditure, subjects were intranasally administered oxytocin (24 IU) and placebo, respectively, at 0942 hours (nose symbol). At 1030 hours,
45 min after substance administration, subjects were allowed to eat ad libitum from a free-choice test buffet for 30 min. About 60 min after
termination of the buffet, at 1200 hours, olfactory function was assessed, and at 1235 hours, 95 min after the end of the buffet, snack intake was
measured under the pretext of a taste-rating task. Throughout the sessions, mood, hunger, thirst and vigilance were assessed, and blood samples
were taken (syringe symbols). Central panels indicate mean± s.e.m. total intake (kcal) from the test breakfast after placebo (white bars) or oxytocin
(black bars) administration in obese (n=18) and normal-weight men (n=20) (b) and individual total food intake with values of both sessions
connected by lines in obese men (c), as well as total snack intake in obese and normal-weight men (d) (Data of normal-weight men reprinted with
permission from ref. 5; copyright 2013 American Diabetes Association.). Lower panels depict, in the group of obese men, snack intake (kcal)
according to snack categories (e), individual total snack intake with individual values of both sessions connected by lines (f), as well as resting
energy expenditure during the baseline (0910–0940 hours), post-treatment (0945–1015 hours) and postprandial periods (1110–1140 hours) (g).
#Po0.08, *Po0.05, **Po0.01 for comparisons between conditions (paired, two-sided t-tests).
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Ott et al.5 Degrees of freedom were corrected using the Greenhouse-
Geisser procedure. Areas under the curve (AUC) were calculated according
to the trapezoidal rule. Signiﬁcant ANOVA and AUC effects were speciﬁed
by pairwise two-sided t-tests. For blood parameters, baseline adjustment
was achieved by subtracting individual baseline values from individual
post-intervention measurements. All data are presented as means± s.e.m.
A P-value o0.05 was considered signiﬁcant.
RESULTS
Oxytocin reduces food intake to a greater extent in obese than
normal-weight men
In the obese subjects, oxytocin in comparison to placebo-reduced
overall food consumption from the breakfast buffet by ~ 10%
(F(1,17) = 5.26, Po0.04 for treatment; Table 3 and Figures 1b and c).
Table 2. Composition of the test buffet
Food Weight (g) Energy (kcal) Carbohydrate (g) Fat (g) Protein (g)
Neutral
Whole wheat bread 165 360 71 2.3 12
Wheat rolls 240 275 122.4 3.4 6.3
White bread 30 72 14.6 0.4 2.2
Butter 120 928 0.7 99.8 0.8
Whole milk 750 491 36 26.3 24.8
Sweet
Strawberry jam 50 147 35.8 0.1 0.1
Hazelnut spread 40 218 21.6 12.8 2.8
Honey 40 123 30 0 0.1
Sugar 24 98 24 0 0
Fruit curd 125 140 19.3 3.3 7.7
Vanilla pudding 125 134 20.8 3.8 3.5
Strawberry milk 200 167 18.2 6.8 7.4
Banana 179 168 38.3 0.4 2
Apple 195 104 22.2 1.2 0.6
Pear 140 78 17.4 0.4 0.7
Orange 180 72 15 0.4 1.8
Tangerine 80 35 8.2 0 0.5
Orange juice 400 173 36 1 4
Savoury
Poultry sausage 40 74 0.1 4.3 8.3
Cervelat sausage 34 120 0.1 10.2 6.1
Sliced cheese 100 374 0 29.2 25.5
Cream cheese (natural) 33 87 0.6 7.8 3
Cream cheese (herbs) 40 124 1 11.6 3.2
Total 3330 4562 553 226 123
All values are rounded to the closest decimal.
Table 3. Calorie intake during the test buffet and snack test
Food type Obese men Normal-weight men P-value (group× treatment)
Placebo Oxytocin P-value Placebo Oxytocin P-value
Eating assessment
Breakfast (kcal)
Total 1421± 99 1274± 92 0.035 1180± 103 1190± 105 0.84 0.07
Carbohydrates 736± 51 659± 57 0.07 517± 41 540± 41 0.43 0.042
Fat 478± 54 430± 44 0.15 517± 54 509± 57 0.84 0.43
Protein 207± 15 187± 13 0.08 145± 16 142± 14 0.82 0.26
Neutral foods 726± 68 681± 74 0.26 519± 62 544± 68 0.42 0.16
Sweet foods 409± 53 375± 48 0.46 346± 40 336± 42 0.64 0.64
Savoury foods 287± 45 219± 31 0.040 314± 38 309± 29 0.91 0.19
Snack test (kcal)
Total 216± 24 162± 27 0.006 283± 44 227± 44 0.03 0.95
Chocolate cookies 144± 25 116± 24 0.030 185± 41 138± 38 0.007 0.34
Rice wafﬂes 22± 5 16± 2 0.26 18± 3 13± 2 0.15 0.78
Salt crackers 51± 11 30± 6 0.07 81± 19 75± 16 0.75 0.49
Mean± s.e.m. values are indicated. P-values are derived from paired, two-tailed t-tests and group× treatment ANOVA interactions, respectively. Obese men,
n= 18; normal-weight men, n= 20.
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In contrast, the normal-weight subjects did not alter their
breakfast intake after oxytocin administration (P40.6 for all
comparisons including treatment ×macronutrients and treat-
ment × food types; F(1,36) = 3.48, P= 0.07 for group × treatment).
The difference between obese and normal-weight men in the
hypophagic effect of oxytocin especially concerned the intake of
carbohydrates (F(1,36) = 4.44, P= 0.042 for group× treatment). In
the obese subjects alone, oxytocin did not exert differential effects
on the intake of macronutrients or food types (all P40.3). In
general, obese ate more than normal-weight participants in the
respective placebo conditions (F(1,36) = 4.27, Po0.05 for group),
in particular more carbohydrates and proteins (F(2,72) = 9.25,
Po0.001 for group ×macronutrient). In both groups, hunger
ratings were comparable at baseline (P40.2) and generally
unaltered by oxytocin (P40.9), falling to comparably low values
of around 12% of the maximal score after breakfast (P40.2;
F(1,36) = 350.54, Po0.001 for time; P40.12 for treatment effects).
Thirst ratings were likewise unaffected by oxytocin (P40.4 for all
comparisons).
In the snack test during the postprandial period, oxytocin in
comparison to placebo induced a reduction in total snack intake
of 22% across all subjects (F(1,36) = 13.37, Po0.001 for treatment;
Table 3 and Figures 1d and f). This effect did not differ between
the obese and the normal-weight groups (F(1,36) = 0.01, P40.9)
although it was of a greater statistical effect size in the obese
(F(1,17) = 9.89, P= 0.006; ωp
2 = 0.31) compared with the normal-
weight participants (F(1,19) = 5.5, P= 0.03; ωp
2 = 0.18). In both
groups, it was especially pronounced for chocolate cookie
consumption (F(2,56) = 3.88, Po0.04 for treatment × snack type;
Table 3; Figure 1e). The oxytocin-induced reductions in total and
chocolate snack intake found in the obese subjects remained
signiﬁcant when corrected for total calorie and carbohydrate
consumption during the preceding breakfast buffet (both
P⩽ 0.003). Although breakfast and snack consumption per se
were unrelated in both conditions (P40.4), the oxytocin-induced
reduction in breakfast intake was inversely related to the
respective attenuation of snack intake (r=− 0.48, Po0.05).
Intake and rated palatability of chocolate cookies by far
exceeded those of the remaining snacks when analyzed across
conditions in the obese subjects (F(1,17) = 70.52, Po0.001 for
snack type). Sweetness and saltiness ratings were highest for
chocolate cookies and salt crackers, respectively (F(2,34) = 221.28,
Po0.001 for snack type × taste). Generally comparable rating
patterns were obtained in the normal-weight subjects (P40.15 for
all group comparisons). Oxytocin did not affect ratings for
chocolate cookies and salt crackers (all P40.15) in the obese
but increased the rated palatability (placebo, 2.89 ± 0.50; oxytocin,
3.82 ± 0.47; Po0.03) and, to a lesser extent, perceived sweetness
of rice wafﬂes (placebo, 1.74 ± 0.40; oxytocin, 2.63 ± 0.61; Po0.06).
Energy expenditure is not acutely affected by oxytocin
administration
Oxytocin did not alter resting energy expenditure assessed by
indirect calorimetry during the entire experimental period in the
obese (F(1,17) = 0.03, P40.87 for treatment × time; F(1,17) = 0.32,
P40.58 for treatment; Figure 1g) and the normal-weight subjects
(all P40.12; F(1,36) = 0.47, P40.49 for group × treatment × time).
The rise in energy expenditure by ~ 22% found in the obese
subjects between the fasting state (baseline) and the postprandial
state reﬂects diet-induced thermogenesis (that is, the energy
emitted as heat during metabolizing of food; F(1,17) = 200.91,
Po0.001 for time). In the postprandial period, oxytocin compared
with placebo appeared to decrease respiratory quotient (placebo,
0.90 ± 0.02; oxytocin, 0.83 ± 0.02) and carbohydrate utilization
(placebo, 0.26 ± 0.03 g min− 1; oxytocin, 0.17 ± 0.02 g min− 1;
both P= 0.02) whereas increasing fat utilization (placebo,
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Figure 2. Blood parameters. Mean± s.e.m. concentrations of plasma adrenocorticotropic hormone (a), serum cortisol (b), plasma glucose (c),
serum insulin (d), serum C-peptide (e) and plasma NEFA (f) assessed before (averaged across the 0915 hours and 0930 hours baseline values)
and after intranasal administration (vertical dotted line) of oxytocin (24 IU; black circles and solid lines) and placebo (vehicle; white circles and
dotted lines) in obese men (n= 18). Subjects ate a test breakfast from 1030–1100 hours and ingested snacks under the pretext of a taste test
from 1235–1245 hours. Mean baseline values of both conditions are averaged to a common baseline. *Po0.05, tPo0.1 for comparisons
between conditions (pairwise two-sided t-tests).
Oxytocin and food intake in obese and lean men
M Thienel et al
1711
International Journal of Obesity (2016) 1707 – 1714
0.05 ± 0.01 g min− 1; oxytocin, 0.10 ± 0.01 g min− 1; P= 0.01) in the
obese group. However, these effects were no longer signiﬁcant
when the analysis of respiratory quotient was corrected for total
breakfast calorie intake and analyses of carbohydrate oxidation
and fat utilization were corrected for carbohydrate and fat intake,
respectively (all P40.17).
Oxytocin reduces HPA axis activity and the glucose response to
food intake in obese and normal-weight subjects
During baseline, none of the blood parameters differed between
conditions (all P40.18). Oxytocin exerted a suppressive effect on
fasting HPA axis activity in the obese men, reducing plasma
adrenocorticotropic hormone and serum cortisol concentrations
between administration and breakfast intake (F(1,17) = 6.20,
P= 0.02; F(1,17) = 5.81, Po0.03, respectively, for treatment effects,
and t(17) = 2.65, Po0.02; t(17) = 2.30, P= 0.03, respectively, for the
difference in AUC0930-1025 hours; Figures 2a and b), whereas
concentrations were comparable between conditions after break-
fast (all P⩾ 0.12 for respective comparisons). In the normal-weight
individuals respective effects extended to the postprandial
period5 but still were largely comparable to the pattern found in
obese subjects (P40.14 for respective group× treatment
interactions). Supplementary analyses in the group of obese
subjects indicated that the oxytocin-induced decreases in pre-
prandial cortisol concentrations (AUC0930-1025 hours) were not
signiﬁcantly correlated with measures of breakfast intake
(all P40.72). Likewise, decreases in postprandial cortisol levels
(AUC1100-1145 hours) were not signiﬁcantly correlated with cookie
intake (all P40.12, Pearson’s coefﬁcients).
Circulating concentrations of glucose, lactate, insulin, and
C-peptide showed the expected meal-related increases across
conditions in the obese participants (all Po0.001 for time;
Figures 2c–e). Whereas levels of lactate, insulin and C-peptide
were not affected by oxytocin administration (all P40.19),
oxytocin exerted a sustained suppressive effect on glucose
levels during the postprandial period (F(3,50) = 3.77, Po0.02
for treatment × time; Figure 2c). This effect was still evident
when adjusted for preceding total and carbohydrate-speciﬁc
breakfast intake (both Po0.05), but statistically unrelated to the
oxytocin-induced decrease in cortisol concentrations (P40.43).
An oxytocin-triggered reduction in postprandial glucose levels
was likewise found in normal-weight individuals (F(1,36) = 0.15,
P= 0.7 for group × treatment). In the obese subjects, total plasma
NEFA concentrations were suppressed after breakfast intake
(F(1,19) = 131.42, Po0.001 for time) without signiﬁcant treatment
effects (P40.67; Figure 2f); circulating concentrations of growth
hormone were comparable between conditions (all P40.24).
Olfactory performance, mood, vigilance, perceived trustworthiness
and treatment awareness
In the olfactory task, no treatment effects on perceptual thresh-
olds, olfactory discrimination and olfactory identiﬁcation emerged
in the obese participants (all P40.17). Self-rated mood, reaction
times in the vigilance task and the perceived trustworthiness of
the experimenter were likewise unaffected (all P40.27). Eight of
the 18 participants (44%) correctly guessed their respective
treatment conditions (χ2 (3;N= 18) = 2.68, P40.6), indicating that
the participants overall gained no treatment awareness. All of
these results were well comparable with the ﬁndings in the group
of normal-weight subjects.5
DISCUSSION
We demonstrate that the acute intranasal administration of oxytocin
inhibits reward- but also hunger-driven food intake in obese men
and that this effect is not compensated by changes in energy
expenditure. In normal-weight men, the oxytocin-induced reduction
in calorie consumption was restricted to snacking, indicating that the
inhibitory effect of oxytocin on food intake is generally larger in
obese than normal-weight subjects. Oxytocin moreover attenuated
secretory activity of the HPA axis and curbed the postprandial
excursion of glucose levels in obese and normal-weight men,
suggesting an insulin-sensitizing action of the hormone.
Oxytocin has been shown in a number of experiments in
rodents to inhibit feeding after intracerebroventricular
injection25,26 as well as after peripheral administration, which
both supposedly trigger hypothalamic oxytocin release in a feed-
forward fashion.2,27 Recently, comparable effects have been
obtained after intranasal administration.28 Oxytocin’s restraining
effect on snacking in the postprandial period may be mediated via
oxytocinergic projections to the brain reward circuit,29 an
assumption supported by signs of oxytocin-induced enhance-
ments in the perceived palatability and sweetness of the
moderately appealing snacks (rice wafﬂes) offered to our obese
subjects. The fact that the attenuating effect of oxytocin on snack
intake focused on chocolate cookies, which were preferentially
eaten and rated most palatable, further suggests a strong reward-
related component of the observed oxytocin action.
In the obese in contrast to normal-weight subjects, the
hypophagic effect of oxytocin clearly pertained to meal intake in
the fasted state, decreasing calorie consumption from the
breakfast buffet by 10%. The conclusion that oxytocin elicits
stronger effects in obese than normal-weight humans is
supported by ﬁndings of more pronounced weight-lowering
oxytocin effects in diet-induced obese compared to control rats,
which were associated with stronger oxytocin-triggered increases
in c-Fos expression in the area postrema and the nucleus of the
solitary tract of the hindbrain.2 Moreover, prolonged anorexigenic
effects of oxytocin have been reported in mice kept on a high-fat
diet in comparison to control animals.27 Enhanced oxytocin
sensitivity in the obese state has been assumed to be mediated
via improved high-afﬁnity receptor binding of oxytocin due to
elevated cholesterol levels,4 and would be in line with reports that
circulating oxytocin concentrations, which were not measured in
the present study, are inversely related to BMI and waist
circumference.30 In recent experiments by Lawson and colleagues
that focused on oxytocin effects in the fasted state,10 ad libitum
energy intake was reduced by oxytocin in both normal- and
overweight men. The contrast to our results might stem from
differences in study design including the more pronounced
induction of food-anticipatory processes in the former study.10
Taking into account potential rebound effects, our study indicates
that the impact of oxytocin on breakfast intake in obese men is
not compensated for by increases in postprandial thermogenesis
and is still evident when subjects are allowed to snack. In
conjunction with our observation that stronger anorexigenic
effects of oxytocin during breakfast are associated with relatively
smaller respective reductions in snack intake, this pattern points
to a global, albeit tightly regulated enhancement of satiety
signalling by oxytocin. This effect is not readily reﬂected in
subjective hunger ratings which accords with the general
treatment unawareness of our subjects. In line with our results,
pilot data suggest that long-term oxytocin administration may
support weight loss in obese patients.11
The ﬁnding of reduced breakfast intake after oxytocin admin-
istration in the fasted state suggests that the peptide restrains
hunger-driven, primarily homeostatically regulated eating,
although under normal circumstances ingestive behaviour trig-
gered by food deprivation also involves a strong hedonic
component. Our analyses did not yield indicators that the
inhibitory effect of oxytocin on breakfast intake in the obese
men focused on such hedonic aspects of food consumption or
could be considered a mere consequence of oxytocin acting on
reward processing. Still, in obese compared with normal-weight
individuals, brain reward circuits show greater activation in
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response to palatable versus bland foods31 whereas fronto-cortical
inhibitory control of food intake appears to be reduced.32
Therefore, the enhanced hypophagic effect of oxytocin in obese
compared with normal-weight subjects may also be interpreted
against the background of a stronger reinforcing quality of food
intake and the tendency to overeat pleasurable food in obesity.33
In line with this, our obese subjects consumed ~ 240 kcal more
than the normal-weight subjects in the respective placebo
conditions. In animal experiments, oxytocin receptor antagonists
acutely attenuate the anorexigenic impact of hormones like
corticotropin-releasing hormone,34 whereas alpha-melanocyte
stimulating hormone, a catabolic messenger, triggers oxytocin
release from supraoptic neurons.35 Oxytocin might furthermore
restrain food intake by acting on downstream mediators of the
leptin signal36 and enhancing cholecystokinin signalling.10 Tests of
olfactory function in our experiments indicated that the decrease
in food intake most likely was not mediated by direct effects on
sensory processing. Biasing effects on ingestive behaviour related
to demand characteristics and social desirability were excluded by
respective interviews.
Oxytocin administration did not induce signiﬁcant alterations in
fasting and postprandial resting energy expenditure. Signs of
decreases in the respiratory quotient and carbohydrate utilization
and respective increases in fat utilization emerging in the obese
subjects during the postprandial period disappeared after
adjustment for preceding calorie intake, suggesting that they
might rather be attributed to oxytocin-induced decreases in
macronutrient consumption. In diet-induced obese rats losing
weight during systemic chronic oxytocin administration, the
decrease in energy expenditure normally associated with weight
loss was prevented by oxytocin, probably via effects on
hypothalamic thermoregulation.2 In obese nonhuman primates,
chronic subcutaneous administration of oxytocin increased energy
expenditure in the dark cycle by 14%.3 Thus, our ﬁnding suggests
that rather than exerting acute effects on energy expenditure,
oxytocin contributes to its regulation on a long-term basis, which
might turn out to be a critical factor in future clinical applications.
Oxytocin blunted plasma glucose excursions during the
postprandial period in obese as well as normal-weight subjects.
Notably, this effect was still evident after correcting the data for
differences in calorie and carbohydrate intake from the breakfast
buffet, which suggests an oxytocin-induced improvement in
insulin sensitivity. Accordingly, oxytocin enhanced insulin sensi-
tivity and glucose tolerance in rodent models of diet-induced
obesity independent of its effects on body weight2 and also in
rhesus monkeys with diet-induced obesity.3 In the study by
Lawson and coworkers,10 intranasal oxytocin reduced fasting
insulin secretion without affecting glucose levels, which also
implies insulin-sensitizing properties of oxytocin and underlines
that the role of oxytocin in glucose homeostasis in humans is in
need of further investigation. The reduction in HPA axis activity by
oxytocin extends previous ﬁndings of an attenuating impact of
intranasal oxytocin on cortisol secretion in response to stress.37
Acute and chronic activation of endocrine stress axes facilitates
the intake of ‘comfort food’, that is, highly palatable food.38 Vice
versa, consuming sucrose reduces HPA axis activity in a negative
feedback loop by activation of central nervous reward circuits.39
With regard to the link between emotional regulation and food
intake,33 a mediation of oxytocin’s attenuating impact on food
intake via reductions in HPA axis activity might be expected to be
of particular relevance in obese subjects. However, in our studies
the two phenomena were statistically related only in normal-
weight participants.5
In summary, our study indicates a restraining effect of oxytocin
on hunger- and reward-driven eating behaviour in obese humans
that goes along with a suppression of HPA axis activity and signs
of enhanced peripheral insulin sensitivity. In contrast to messen-
gers like insulin and leptin, whose anorexigenic impact is blunted
when body weight is increased,40 oxytocin exerts a potent acute
inhibition of food intake in obese subjects which even surpasses
the effect found in normal-weight humans. These results clearly
warrant further investigations on long-term oxytocin effects in
metabolic disorders.
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